来那度胺联合硼替佐米和地塞米松治疗 多发性骨髓瘤的疗效
2025-07-01向立丽王倩蒙延娜付杰张璞
中图分类号:R733.3 文献标志码:A DOI:10.11958/20250356
Abstract:ObjectiveTo investigate the eficacyoflenalidomide combined with bortezomibanddexamethasone in the treatmentof multiple myeloma (MM)and their efectson heat shock protein90(HSP90)mRNA,miR-28-5p,anti-tartrate acid phosphatase 5b(TRACP-5b)and highmobilitygroup protein B1(HMGB1).MethodsEighty patients with newly diagnosed MM wereselectedanddividedinto thetwo-combination group(4O patients treated with bortezomib and dexamethasone)and the three-combination group (40 patients treated with bortezomibanddexamethasone combined with lenalidomide)acording tothetreatmentmodalities.Real-timefluorescencequantitativepolymerasechainreactionwas used to detect HSP90 mRNA and miR-28-5p levels.Enzyme-linked immunosorbent asy was used to detect TRACP-5b and HMGB1 levels.The clinical eficacy of the2 groups was compared.Levels of HSP90 mRNA,miR-28-5p,TRACP-5b, HMGB1,theimmunecellfunction,renalfunction indexes and the incidence ofadversereactions were comparedbefore and aftertreatment.ResultsThetotaleffectiverateof thethree-combinationgroupwashigherthanthatofthetwo-combination groups (92.50% vs. 75.00% , Plt;0.05 ).Compared with the pretreatment, the levels of HSP9O mRNA,TRACP-5b,blood creatinie (SCr),andurea nitrogen (BUN)decreased inthe2 groupsafter treatment,and which waslower inthethreecombination group than that in the two-combination groups.The levels of miR-28-5p,HMGB1,CD 4+ ,CD3 + and CD4+/CD8+ were elevatedinthe2 groups,and the levels were higher inthethree-combination group thanthose inthetwo-combination group( Plt;0.05 ).There was no significant differencein the incidence of adverse reactions between the two groups. ConclusionLenalidomidecombined withbortezomibanddexamethasone is clinicalleffective,safeandreliable in the treatment of MM.
Keywords:multiplemyeloma; lenalidomide;bortezomib;dexamethasone;HSP9O heat-shockproteins;HMGB1 protein;miR-28-5p;tartrateresistantacidphosphatase5b isoenzyme
多发性骨髓瘤(multiple myeloma,MM)是一种血液系统恶性肿瘤,主要表现为贫血、肾损伤及骨痛等[1-2]。研究显示,MM是世界上发病率第2的恶性血液系统疾病,且男性发病多于女性[3-4]。据2018年的统计学数据,我国MM的发病率呈不断升高的趋势,且患者的5年生存率低于日本和美国[5]。合适的治疗方案可以延缓MM的病情进展,提高患者的生存率6。目前多采取联合用药进行辅助治疗,其中以应用地塞米松联合硼替佐米为主,该方案对MM效果良好,但部分患者的疼痛及生活质量仍无法得到改善[7]。针对此现象,需进一步探索联合用药方案来提高治疗效果。来那度胺是一种免疫调节剂,可改善机体的免疫功能,具有明显的抗癌效果,将其应用于多发性骨髓瘤的临床治疗中,可有效起到调节免疫、抗肿瘤血管生成等作用[8-9]。热休克蛋白90(HSP90)是一种与细胞增殖、调亡及分化有关的基因,其水平对MM患者病情及预后评估有潜在参考价值[10]。miR-28-5p是新近发现的与肿瘤侵袭转移有关的miRNA。高迁移率族蛋白B1(HMGB1)是一种炎性因子。研究表明MM患者血清 miR-28- 5p表达水平降低,HMGB1表达水平升高,二者均与MM患者预后有关[]。抗酒石酸酸性磷酸酶5b(TRACP-5b)主要来源于活化的破骨细胞。范小红等[12]研究发现TRACP-5b参与了MM的发生和发展,对预测MM患者1年内发生死亡具有较高的价值。基于此,本研究主要对来那度胺联合硼替佐米和地塞米松治疗MM效果及对HSP90mRNA、miR-28-5p、TRACP-5b、HMGB1水平的影响进行分析,旨在为临床中MM的治疗提供新的研究方向。
1资料与方法……p>
